Quest Diagnostics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| DGX | TTWO | |
|---|---|---|
Market Cap | $25.48B | $39.15B |
Volume | 941,866 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $247.45 | $262.29 |
52-Week Low | $173.49 | $189.69 |
Typical Hold Time | 56 Days | 111 Days |
Enterprise Value | $31.23B | $40.27B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, while the company reaffirmed the GTA VI launch date for November 19, 2026. Financials reveal negative net income margins and elevated debt levels, though revenue growth is projected to $6.7B in 2026. The stock is near its pivot point of $209, with support at $206 and resistance at $212.
The outlook hinges on GTA VI's successful launch driving revenue growth and profitability improvements. Risks include execution challenges, competitive pressures, and high valuation multiples. Analyst optimism, with a $292.30 price target, suggests significant upside if operational targets are met, but investors must weigh near-term losses against long-term game release catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →